Two Cases Showing That Cilostazol Administration Leads to an Increase in Cerebral Blood Flow and Has a Positive Effect on Rehabilitation

Didn't your competent? doctor create a protocol on its' use a long time ago? NO? Then why are you seeing an incompetent doctor? And why is the board of directors still employing an incompetent doctor?

In my opinion competent doctors are up-to-date on ALL stroke research! No excuses allowed!

• cilostazol (19 posts to August 2013)

 

Two Cases Showing That Cilostazol Administration Leads to an Increase in Cerebral Blood Flow and Has a Positive Effect on Rehabilitation

Shuji Matsumoto • Rintaro Ohama • Takashi Hoei • Ryuji Tojo • Toshihiro Nakamura

Published: March 18, 2024

DOI: 10.7759/cureus.56376 

  Peer-Reviewed

Cite this article as: Matsumoto S, Ohama R, Hoei T, et al. (March 18, 2024) Two Cases Showing That Cilostazol Administration Leads to an Increase in Cerebral Blood Flow and Has a Positive Effect on Rehabilitation. Cureus 16(3): e56376. doi:10.7759/cureus.56376

• Article
• Authors etc.
• Metrics
• Media
• Comments

Abstract

Cilostazol is a drug that has both antiplatelet and vasodilatory effects. To examine the effects of cilostazol on cerebral blood flow and rehabilitation following stroke, cilostazol was administered to two patients with chronic atherothrombotic cerebral infarction. In both patients, cilostazol administration effectively increased cerebral blood flow and promoted rehabilitation. Therefore, cilostazol was considered to be a useful agent for improving the clinical condition of patients suffering from chronic cerebral infarction. Further clinical studies on the effective use of cilostazol for rehabilitation in stroke patients are needed.

Introduction

Although the mortality rate as a result of stroke is declining, the incidence of stroke itself is increasing. As a result, the number of patients with chronic cerebral infarction is also rising, such that the clinical management of this condition is likely to become a major future health issue. The global number of deaths from stroke is projected to increase from 2.04 million to 3.29 million between 1990 and 2019 and to 4.9 million by 2030 [1].

There is now widespread evidence that antiplatelet drugs are an effective treatment for atherothrombotic cerebral infarction [2], but there are currently no indices as to what types of antiplatelet drugs are most effective or at what stage they should be administered. In addition to an antiplatelet effect [3] due to cyclic guanosine monophosphate (cGMP)-inhibited phosphodiesterase, cilostazol also reportedly has pleiotropic and vasodilatory effects [4,5], improves vascular endothelial function [6] and suppresses vascular smooth muscle growth [7]. Cilostazol reportedly enhances cerebral blood flow in cases of chronic cerebral infarction [8]. However, its effects on physiological functions, the performance of activities of daily living (ADL), and cognitive function have not been investigated previously.

We administered cilostazol to two patients with chronic atherothrombotic cerebral infarction and evaluated the effects of the drug on cerebral blood flow and rehabilitation.

More at link.